Our Story
Company Founding:
CellBion Co., Ltd. was established in July 2010 with the vision of revolutionizing the radiopharmaceutical industry. Since its inception, CellBion has been dedicated to the development and commercialization of innovative radioligand therapies to address unmet medical needs, focusing on improving patient outcomes and advancing healthcare through groundbreaking research and cutting-edge technology.
Major Achievements:
Over the years, CellBion has achieved several significant milestones that demonstrate the company's commitment to research, innovation, and quality.
Some of our major achievements include:
In March 2022, our pipeline DGUL was designated as an Orphan drug by the Ministry of Food and Drug Safety (MFDS).
In August 2018, we received approval for the clinical phase 1 trial of Tc-99m-MSA (KFDA, No. 31789).
In December 2016, CellBion was awarded the 2016 Minister Award for Excellent Bio R&D Company by the Ministry of Trade, Industry, and Energy, Republic of Korea.
In May 2016, we established the Bio R&D Center at Healthcare Innovation Park in SNU Bundang Hospital, further expanding our research capabilities.
In December 2015, our Project MSA was designated as Pharm-Navi No. 5 (Commercialization and Globalization Support Program) by the Ministry of Food and Drug Safety (MFDS).
In March 2022, our pipeline DGUL was designated as an Orphan drug by the Ministry of Food and Drug Safety (MFDS).
In August 2018, we received approval for the clinical phase 1 trial of Tc-99m-MSA (KFDA, No. 31789).
In December 2016, CellBion was awarded the 2016 Minister Award for Excellent Bio R&D Company by the Ministry of Trade, Industry, and Energy, Republic of Korea.
In May 2016, we established the Bio R&D Center at Healthcare Innovation Park in SNU Bundang Hospital, further expanding our research capabilities.
In December 2015, our Project MSA was designated as Pharm-Navi No. 5 (Commercialization and Globalization Support Program) by the Ministry of Food and Drug Safety (MFDS).
Timeline:
May 2023:
Prostate cancer diagnostic (NGUL) clinical phase 3 trial IND planned and Tc-MSA clinical phase 2
Aug. 2021:
Completion of prostate cancer diagnostic clinical phase 1 trial and KDDF project selection (DGUL, clinical phase 1/2 trial in progress)
Mar. 2020:
Prostate cancer diagnostic (NGUL) clinical phase 1 trial IND approval and prostate cancer therapeutic (DGUL) clinical phase 1/2 trial IND approval
Sep. 2019:
PSMA-NGUL comparative investigator trial (India) and Tc-MSA clinical phase 1 trial IND approval
Sep. 2018:
Awarded with Minister Industry Award by Ministry of Science and Technology (No. 25635)
Aug. 2018:
Approved clinical phase 1 trial of Tc-99m-MSA (KFDA, No. 31789)
May. 2018:
Selected as a promising bio-IP business by Ministry of Commerce, Industry and Energy
April. 2018:
Signed a contract with a stock listing supervisor (Korea Investment & Securities Co., Ltd)
Feb. 2018:
Selected as a new drug development project by the Ministry of Health and Welfare
Jan. 2017:
Registered Wholesale Drug Distributor License and License for Cosmetics Manufacturer
Dec. 2016:
Awarded with 2016 Minister Award for Excellent Bio R&D company by the Ministry of Trade, Industry and Energy, Republic of Korea
May. 2016:
Establishment of Bio R&D Center at Healthcare Innovation Park in SNU Bundang Hospital
Dec. 2015:
Project MSA designated as Pharm-Navi No. 5 by Ministry of Food and Drug Safety (MFDS)
Jul. 2015:
Cellbion Co., Ltd. annexed R&D Lab of recognition (Ministry of Science, ICT and Future Planning/Korean Industrial Technology Association)
Jun. 2015:
Establishment of Pharmaceutical Research Institute at SNU Cancer Research Institute, Seoul, Korea
Jun. 2015:
Accredited as Venture Company by Korean Venture Capital Association
Oct. 2014:
Technology transfer agreement for Ga68 NOTA-MSA KIT with Seoul National University (SNU) R&DB Foundation
Jul. 2010:
Establishment of CellBion Co., Ltd.
Prostate cancer diagnostic (NGUL) clinical phase 3 trial IND planned and Tc-MSA clinical phase 2
Aug. 2021:
Completion of prostate cancer diagnostic clinical phase 1 trial and KDDF project selection (DGUL, clinical phase 1/2 trial in progress)
Mar. 2020:
Prostate cancer diagnostic (NGUL) clinical phase 1 trial IND approval and prostate cancer therapeutic (DGUL) clinical phase 1/2 trial IND approval
Sep. 2019:
PSMA-NGUL comparative investigator trial (India) and Tc-MSA clinical phase 1 trial IND approval
Sep. 2018:
Awarded with Minister Industry Award by Ministry of Science and Technology (No. 25635)
Aug. 2018:
Approved clinical phase 1 trial of Tc-99m-MSA (KFDA, No. 31789)
May. 2018:
Selected as a promising bio-IP business by Ministry of Commerce, Industry and Energy
April. 2018:
Signed a contract with a stock listing supervisor (Korea Investment & Securities Co., Ltd)
Feb. 2018:
Selected as a new drug development project by the Ministry of Health and Welfare
Jan. 2017:
Registered Wholesale Drug Distributor License and License for Cosmetics Manufacturer
Dec. 2016:
Awarded with 2016 Minister Award for Excellent Bio R&D company by the Ministry of Trade, Industry and Energy, Republic of Korea
May. 2016:
Establishment of Bio R&D Center at Healthcare Innovation Park in SNU Bundang Hospital
Dec. 2015:
Project MSA designated as Pharm-Navi No. 5 by Ministry of Food and Drug Safety (MFDS)
Jul. 2015:
Cellbion Co., Ltd. annexed R&D Lab of recognition (Ministry of Science, ICT and Future Planning/Korean Industrial Technology Association)
Jun. 2015:
Establishment of Pharmaceutical Research Institute at SNU Cancer Research Institute, Seoul, Korea
Jun. 2015:
Accredited as Venture Company by Korean Venture Capital Association
Oct. 2014:
Technology transfer agreement for Ga68 NOTA-MSA KIT with Seoul National University (SNU) R&DB Foundation
Jul. 2010:
Establishment of CellBion Co., Ltd.
